No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis - 28/01/23
Doi : 10.1016/j.jinf.2022.11.022
Huzaifa Ahmad Cheema a, ⁎ 
, Arman Shafiee b, c, Mohammad Mobin Teymouri Athar d, Abia Shahid a, Rehmat Ullah Awan e, Ahmed M Afifi f, Jaffer Shah g, Prasun K Jalal h
, Arman Shafiee b, c, Mohammad Mobin Teymouri Athar d, Abia Shahid a, Rehmat Ullah Awan e, Ahmed M Afifi f, Jaffer Shah g, Prasun K Jalal h a Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Nila Gumbad Chowk, Neela Gumbad, Lahore, Punjab 54000, Pakistan
b Clinical Research Development Unit, Alborz University of Medical Sciences, Karaj, Iran
c Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
d School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
e Department of Medicine, Ochsner Rush Medical Center, Meridian, MS, United States
f Department of Gastroenterology, Hepatology & Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX, United States
g New York State Department of Health, Albany, NY, United States
h Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States
⁎Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | We assessed the effect of famotidine administration in COVID-19 patients. |
• | We included 10 studies out of which 3 were randomized controlled trials (RCTs). |
• | Famotidine does not reduce mortality or hasten recovery in COVID-19 patients. |
• | Large-scale RCTs are needed to investigate its efficacy. |
Keywords : Famotidine, COVID-19, SARS-CoV-2, Histamine H2-receptor antagonists
Plan
© 2022
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 86 - N° 2
P. 154-225 - février 2023 Retour au numéro
Article précédent
- Changes in the prevalence of respiratory pathogens in children due to the COVID-19 pandemic: A systematic review and meta-analysis
- Yuyi Tang, Xiangyang Dang, Meng Lv, Susan-L Norris, Yaolong Chen, Luo Ren, Enmei Liu
- Deficiency of HTR4 and ADRB1 caused by SARS-CoV-2 spike may partially explain multiple COVID-19 related syndromes including depression, cognitive impairment, loss of appetite, heart failure, and hypertension
- Lu Lv, Ang Li, Lu Jiang, Leiliang Zhang
Bienvenue sur EM-consulte, la référence des professionnels de santé.